Maven Bio Analysis: $500K Raised
What is Maven Bio?
Maven Bio provides AI-powered investment research, data analytics, and automated reporting for life sciences teams. Its platform returns cited answers from trials and therapeutic market data, and it organizes comparisons with Smart Tables and report generation tools. The company positions the product for pharma, biotech, consulting, and investment professionals who need source-backed research on competitors, pipelines, and clinical studies.
Location
911 S Primrose Ave, Monrovia, California 91016, United States
Employees
1-10
Founded
2023
Business Model
AI platform for BioPharma; revenue from subscriptions and consulting services.
Investors
- Y Combinator
- NVO Capital
Product Features & Capabilities
- Maven Workflows, Maven Atlas, Maven Compass, Maven Assistant, collaborative research tasks, interactive indication landscapes, natural language search for data, instant answers with primary sources.
Pricing
- Team Plan:
- 1500 Research Credits / Month
- 1500 Export Credits / Month
- Workflows
- Atlas
- Compass
- Assistant
- Database Access
- Enterprise Plan:
- Everything in Team
- Unlimited Research Credits
- 3000 Export Credits / Month
- Personalized Onboarding
- Priority Support
- Custom Plan:
- Everything in Enterprise
- Integration with Custom Data
- Custom Workflows
- Custom Ontologies
- Private Deployments
- Dedicated Support
- Personalized Training
- Custom Branding
How much Maven Bio raised
Pre-Seed - $500,000
September 6, 2023Lead Investor: Y Combinator, NVO Capital
Who are the founders of Maven Bio
MB
Michael Brady
Founder
AM
Arjun Murthy
Founder
Market Focus
Maven Bio primarily focuses on the BioPharma industry, providing a domain-specific AI platform for consultants, investors, and in-house teams to enhance decision-making and reduce manual work.
Competitors Overview
Maven Bio's main competitors in the bio-pharmaceutical AI platform market include:
-
Archon Bio: Ranked 1st among competitors, Archon Bio provides a computational platform for developing protein therapeutics. It has raised $20 million in funding from investors like Alexandria and Madrona Venture Group, giving it a significant financial advantage and established market presence.
-
Promise: Ranked 2nd, Promise offers an AI-based platform for personalized treatment plans and has secured $8.3 million in funding from notable investors such as Pfizer and AstraZeneca. This positions Promise well in the market with a strong focus on personalized medicine.
-
Zhongke Borui: Ranked 3rd, Zhongke Borui operates as an AI-powered drug intelligence platform for life science professionals but has not disclosed any funding information. Its lack of funding may limit its growth compared to its competitors.
Maven Bio is currently ranked 8th among 16 active competitors, indicating it is still establishing its presence in the market. The competitors listed have varying degrees of funding and focus areas, which may provide them with advantages in terms of resources and market reach.
See something that needs updating? Suggest edits to this profile.